White Arrow schreef op 31 juli 2025 10:49:
[...]
Ook een moeilijke vergelijkingsbasis. Staat volgens mij ook in het persbericht.
Outlook 2025
Corbion remains on-track to deliver the previously shared outlook targets on all relevant metrics.
Corbion affirms the key components of full-year guidance as follows:
- Organic growth
o Volume/mix growth: 2-6%
o Adjusted EBITDA growth: > 25%
- Free Cash Flow: > € 85 million
- 2025 year-end covenant net debt/covenant EBITDA: ~1.6x
The impact from the previously enacted tariffs has been largely managed by supply-chain
measures resulting in an insignificant effect on Adjusted EBITDA, which is already accounted for
in the FY outlook.
Sales are expected to increase for the full year driven by volume/mix growth in the Food business
and Health & Nutrition segment. Pricing is expected to be slightly negative while Adjusted
EBITDA margins are expected to increase versus FY 2024.
In Functional Ingredients & Solutions, sales to natural preservation into food end-markets are
expected to continue supporting growth in FY 2025. We continue to see the benefits of
operational excellence and costs savings as well.
All three businesses in the Health & Nutrition segment are expected to contribute to sales and
earnings growth for the segment. In Nutrition, increased sales to non-aquaculture markets, and
expansion to a broader aquaculture customer base will offset the temporary pricing effect on the
non-contracted portion of the aquaculture market in H2 (following lower fish oil prices).
Volume/mix growth in Health & Nutrition is expected for H2, with growth in Q4 more than
offsetting the decline in Q3 (vs high comparable in Q3 2024 of +28% volume/mix growth). We are
successfully entering the human nutrition market with sales growth of omega-3 DHA sales
expected in H2 2025.
Full-year Adjusted EBITDA growth of >25% remains on track.